537 related articles for article (PubMed ID: 15679252)
21. Adjuvant therapy for surgically resected pancreatic adenocarcinoma.
Abbruzzese JL
JAMA; 2008 Mar; 299(9):1066-7. PubMed ID: 18319419
[No Abstract] [Full Text] [Related]
22. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration.
Breslin TM; Hess KR; Harbison DB; Jean ME; Cleary KR; Dackiw AP; Wolff RA; Abbruzzese JL; Janjan NA; Crane CH; Vauthey JN; Lee JE; Pisters PW; Evans DB
Ann Surg Oncol; 2001 Mar; 8(2):123-32. PubMed ID: 11258776
[TBL] [Abstract][Full Text] [Related]
23. Preoperative chemoradiation for patients with locally advanced adenocarcinoma of the pancreas.
White R; Lee C; Anscher M; Gottfried M; Wolff R; Keogan M; Pappas T; Hurwitz H; Tyler D
Ann Surg Oncol; 1999; 6(1):38-45. PubMed ID: 10030414
[TBL] [Abstract][Full Text] [Related]
24. Survival for patients with pancreatic cancer after addition of gemcitabine to Fluorouracil chemoradiation.
Fujita T
JAMA; 2008 Jun; 299(24):2852; author reply 2852-3. PubMed ID: 18577725
[No Abstract] [Full Text] [Related]
25. Long-term follow-up of twenty patients with adenocarcinoma of the pancreas: resection following combined modality therapy.
Cooperman AM; Snady H; Bruckner HW; Hammerman H; Siegel J; Stark B; Bank S
Surg Clin North Am; 2001 Jun; 81(3):699-708. PubMed ID: 11459283
[TBL] [Abstract][Full Text] [Related]
26. Phase I study of twice-weekly gemcitabine and concomitant external-beam radiotherapy in patients with adenocarcinoma of the pancreas.
Pipas JM; Mitchell SE; Barth RJ; Vera-Gimon R; Rathmann J; Meyer LP; Wagman RS; Lewis LD; McDonnell C; Colacchio TA; Perez RP
Int J Radiat Oncol Biol Phys; 2001 Aug; 50(5):1317-22. PubMed ID: 11483344
[TBL] [Abstract][Full Text] [Related]
27. Docetaxel/Gemcitabine followed by gemcitabine and external beam radiotherapy in patients with pancreatic adenocarcinoma.
Pipas JM; Barth RJ; Zaki B; Tsapakos MJ; Suriawinata AA; Bettmann MA; Cates JM; Ripple GH; Sutton JE; Gordon SR; McDonnell CE; Perez RP; Redfield N; Meyer LP; Marshall JF; Cole BF; Colacchio TA
Ann Surg Oncol; 2005 Dec; 12(12):995-1004. PubMed ID: 16252135
[TBL] [Abstract][Full Text] [Related]
28. [Adjuvant and additive therapy for cancer of the pancreas].
Neoptolemos JP; Raraty MG; Ghaneh P; Hickey H; Stocken DD; Dunn JA; Friess H; Büchler MW
Chirurg; 2003 Mar; 74(3):191-201. PubMed ID: 12647075
[TBL] [Abstract][Full Text] [Related]
29. The recent past and future of adjuvant therapy for pancreatic cancer.
Yeo CJ
Ann Surg Oncol; 2003 Jun; 10(5):488-9. PubMed ID: 12794012
[No Abstract] [Full Text] [Related]
30. [Adjuvant treatment of pancreatic cancer].
Oettle H
Zentralbl Chir; 2003 May; 128(5):411-8. PubMed ID: 12813641
[TBL] [Abstract][Full Text] [Related]
31. Evaluation of clinical factors and treatment results in patients with advanced pancreatic cancer.
Brasiūnas V; Brasiūniene B; Juozaityte E; Barauskas G
Medicina (Kaunas); 2004; 40(11):1074-80. PubMed ID: 15547308
[TBL] [Abstract][Full Text] [Related]
32. Adjuvant intra-arterial 5-fluoruracil, leucovorin, epirubicin and carboplatin with or without systemic gemcitabine after curative resection for pancreatic adenocarcinoma.
Cantore M; Serio G; Pederzoli P; Mambrini A; Iacono C; Pulica C; Capelli P; Lombardi M; Torri T; Pacetti P; Pagani M; Fiorentini G
Cancer Chemother Pharmacol; 2006 Oct; 58(4):504-8. PubMed ID: 16633830
[TBL] [Abstract][Full Text] [Related]
33. The case for routine use of adjuvant therapy in pancreatic cancer.
Kennedy EP; Yeo CJ
J Surg Oncol; 2007 Jun; 95(7):597-603. PubMed ID: 17230543
[TBL] [Abstract][Full Text] [Related]
34. Role of adjuvant therapy in the management of pancreatic cancer.
Laheru D; Yeo CJ
Adv Surg; 2005; 39():223-44. PubMed ID: 16250554
[No Abstract] [Full Text] [Related]
35. Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial).
Maurel J; Sánchez-Cabús S; Laquente B; Gaba L; Visa L; Fabregat J; Povés I; Roselló S; Díaz-Beveridge R; Martín-Richard M; Rodriguez J; Sabater L; Conill C; Cambray M; Reig A; Ayuso JR; Valls C; Ferrández A; Bombí JA; Ginés A; García-Albéniz X; Fernández-Cruz L
Cancer Chemother Pharmacol; 2018 Dec; 82(6):935-943. PubMed ID: 30225601
[TBL] [Abstract][Full Text] [Related]
36. Maintenance chemotherapy after chemoradiation improves survival of patients with locally advanced pancreatic carcinoma: a retrospective analysis of prospectively recruited patients.
Brunner TB; Tinkl D; Grabenbauer GG; Meyer T; Brueckl WM; Sauer R
Strahlenther Onkol; 2006 Apr; 182(4):210-5. PubMed ID: 16622622
[TBL] [Abstract][Full Text] [Related]
37. Neoadjuvant strategies for pancreatic cancer.
Evans DB; Wolff RA; Crane CH
Oncology (Williston Park); 2001 Jun; 15(6):727-37; discussion 741-4, 747. PubMed ID: 11430206
[TBL] [Abstract][Full Text] [Related]
38. Neoadjuvant chemoradiation for non-metastatic pancreatic cancer increases margin-negative and node-negative rates at resection.
Berriochoa CA; Abdel-Wahab M; Leyrer CM; Khorana A; Matthew Walsh R; Kumar AMS
J Dig Dis; 2017 Nov; 18(11):642-649. PubMed ID: 29055078
[TBL] [Abstract][Full Text] [Related]
39. [The update on pancreatic cancer chemotherapy].
Brasiūniene B; Juozaityte E; Brasiūnas V; Inciūra A
Medicina (Kaunas); 2003; 39(10):1016-25. PubMed ID: 14578647
[TBL] [Abstract][Full Text] [Related]
40. Chemotherapy in advanced pancreatic adenocarcinoma.
Kollmannsberger C; Peters HD; Fink U
Cancer Treat Rev; 1998 Apr; 24(2):133-56. PubMed ID: 9728423
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
